NKTR-0165

About Nektar Therapeutics

Nektar Therapeutics is dedicated to developing transformative immunomodulatory therapies that restore immune homeostasis in autoimmune and inflammatory diseases. The company's core strategy leverages a deep understanding of immunology to engineer first-in-class agonists targeting upstream regulatory nodes, specifically the IL-2 and TNFR2 pathways, to expand regulatory T cells. With its lead candidate, rezpegaldesleukin, advancing in multiple Phase 2b trials, a seasoned leadership team, and a proven track record of strategic partnerships, Nektar aims to shift treatment paradigms from broad immunosuppression to targeted immune recalibration.

Therapeutic Areas